Carlsmed promotes Jeff Bertolini to COO to support spine surgery growth
At a glance
- $CARL today+2.25%last $17.74
- Vs industry peers+1.76 pts6-peer median +0.49% · ahead
- Since Sep 8+18.3%from the first trade after the story
- 52-week range7.4% below high$8.50 – $19.15
- Cash runway~11 mo$35.9M cash ÷ $3.2M/mo burn · 10-Q
- Coverage0 this week1 in 30 days · too few stories to call a pace
Nothing reported about carlsmed across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Healthcare upside usually comes in discrete events — readouts, approvals and launches — rather than gradual trends.
- How the stock is trading: $CARL +2.25% in the latest session.
- Timing: It came out after the closing bell. The session change shown was settled before the story existed, and the next session is the first that could react.
Where the stock stands
Carlsmed ($CARL) rose 2.25% to $17.74 in the latest session. Over the past month it is up 29.9%. That leaves it 7.4% below its 52-week high of $19.15 and 109% above its low of $8.50. It has been a volatile year: the high was 2.3 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 10, 2026), $CARL lost $12.2M over the quarter to Sep 30, 2026. Operations used $29.0M of cash over the nine months to Sep 30, 2026 — about $3.2M a month — against $35.9M in cash on Sep 30, 2026. At that pace the cash covers about 11 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. It carried $15.4M of debt against $35.9M of cash on Sep 30, 2026 — net cash of $20.5M. The company filed an 8-K — the form for material events — on Sep 8, the same day as this story; it is $CARL's own account and the first thing to read. Figures are as filed with the SEC; the $CARL page has the full statements.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed one newer story on Carlsmed in the last 30 days. It reads neutral.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $CARL page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. Wook AI, at the top of the page, can work out how far $CARL is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on September 8, 2026. $CARL has moved +18.35% ($14.99 to $17.74). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
